FGFR2 and glioblastoma: In GBM, the commonly mutated or amplified RTKs are the epidermal growth factor receptor (EGFR) (57.4%), platelet-derived growth factor receptor (PDGFR) (13.1%), mesenchymal epithelial transition (MET) (1.6%), and fibroblast growth factor receptor 2/3 (FGFR2/3) (3.2%).